

Van K Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4746746/publications.pdf>

Version: 2024-02-01

71
papers

3,771
citations

304743

22
h-index

133252

59
g-index

71
all docs

71
docs citations

71
times ranked

5440
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. <i>Oncologist</i> , 2022, 27, 40-47.	3.7	7
2	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS233-TPS233.	1.6	1
3	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	1.4	2
4	Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. <i>Nature Reviews Cancer</i> , 2022, 22, 317-318.	28.4	4
5	Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 974-984.	0.8	5
6	Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 78-88.	0.8	8
7	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	5.9	10
8	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 137-147.e1.	2.3	17
9	Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 296-305.	0.8	22
10	Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. <i>Clinical Cancer Research</i> , 2021, 27, 120-130.	7.0	21
11	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS148-TPS148.	1.6	2
12	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	7.0	28
13	Comprehensive Clinical and Molecular Characterization of KRAS ^{G12C} -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	3.0	31
14	CEA as a blood-based biomarker in anal cancer. <i>Oncotarget</i> , 2021, 12, 1037-1045.	1.8	4
15	Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA). <i>Annals of Surgical Oncology</i> , 2021, 28, 4095-4097.	1.5	8
16	Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. <i>JAAD Case Reports</i> , 2021, 13, 23-25.	0.8	2
17	Reply from author: Biology is king, but metastasectomy still has a role for properly selected patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, e136-e138.	0.8	1
18	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 643815.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annual Review of Medicine, 2021, 72, 399-413.	12.2	12
20	Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 2412-2422.	1.4	4
21	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2021, , .	2.3	0
22	Using circulating tumor DNA for colon cancer adjuvant therapy: to be or not to be?. Clinical Cancer Research, 2021, , clincanres.3564.2021.	7.0	1
23	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 48-56.e2.	2.3	2
24	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 901-908.	2.4	7
25	Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiotherapy and Oncology, 2020, 151, 56-57.	0.6	1
26	Population-based Screening for <i>BRAF</i> V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clinical Cancer Research, 2020, 26, 4599-4605.	7.0	26
27	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clinical Colorectal Cancer, 2020, 19, e189-e199.	2.3	1
28	Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. Oncologist, 2020, 25, e1628-e1639.	3.7	4
29	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clinical Colorectal Cancer, 2020, 19, 248-255.e6.	2.3	3
30	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal "Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
31	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. Journal of Surgical Oncology, 2020, 121, 984-989.	1.7	1
32	Improvements in Clinical Outcomes for <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4435-4441.	7.0	17
33	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2020, 38, TPS4121-TPS4121.	1.6	3
34	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget, 2020, 11, 1334-1343.	1.8	18
35	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British Journal of Cancer, 2019, 121, 505-510.	6.4	32
36	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. Journal of Surgical Oncology, 2019, 120, 729-735.	1.7	20

#	ARTICLE	IF	CITATIONS
37	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	27.0	918
38	Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. <i>JAMA Oncology</i> , 2019, 5, 1101.	7.1	2
39	Clinical and molecular characterization of early-onset colorectal cancer. <i>Cancer</i> , 2019, 125, 2002-2010.	4.1	212
40	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 53-60.	0.5	4
41	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Annals of Oncology</i> , 2019, 30, 243-249.	1.2	170
42	Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral. <i>Clinical Cancer Research</i> , 2019, 25, 2030-2032.	7.0	7
43	Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3604-3604.	1.6	8
44	Clinical characteristics of colitis induced by taxane-based chemotherapy. <i>Annals of Gastroenterology</i> , 2019, 33, 59-67.	0.6	12
45	A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e18206-e18206.	1.6	3
46	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15060-e15060.	1.6	0
47	Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3587-3587.	1.6	0
48	Meat consumption and BRAF mutation status in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15135-e15135.	1.6	0
49	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	7.0	225
50	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 903-908.	4.9	10
51	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , 2018, 17, e699-e709.	2.3	34
52	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	10.7	322
53	Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Molecular Cancer Research</i> , 2017, 15, 1542-1550.	3.4	59
54	Metastatic Anal Cancer and Novel Agents. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 133-142.	1.5	7

#	ARTICLE	IF	CITATIONS
55	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS ONE, 2017, 12, e0183949.	2.5	25
56	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget, 2016, 7, 67495-67506.	1.8	42
57	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. Oncotarget, 2016, 7, 54627-54631.	1.8	53
58	Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. Journal of Gastrointestinal Oncology, 2016, 7, 721-726.	1.4	7
59	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	9.4	192
60	Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer, 2016, 114, 1352-1361.	6.4	81
61	Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. Pancreatology, 2016, 16, 153-156.	1.1	11
62	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist, 2015, 20, 1247-1252.	3.7	28
63	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. Current Colorectal Cancer Reports, 2015, 11, 303-310.	0.5	0
64	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4032-4038.	1.6	583
65	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With <i>BRAF</i> -Mutated Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 164-171.	2.3	108
66	BRAF inhibitors in clinical oncology. F1000prime Reports, 2013, 5, 11.	5.9	32
67	Clinical biomarkers in colorectal cancer. Clinical Advances in Hematology and Oncology, 2013, 11, 768-76.	0.3	3
68	SEVERE THROMBOCYTOPENIA WITH IRON DEFICIENCY ANEMIA. Pediatric Hematology and Oncology, 2010, 27, 413-419.	0.8	21
69	Rhombohedral crystals of <i>Mycobacterium tuberculosis</i> phosphopantetheine adenylyltransferase. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 195-196.	2.5	6
70	Substrate-induced asymmetry and channel closure revealed by the apoenzyme structure of <i>Mycobacterium tuberculosis</i> phosphopantetheine adenylyltransferase. Protein Science, 2004, 13, 2547-2552.	7.6	29
71	Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstetric Medicine, 0, , 1753495X2110412.	1.1	4